, Volume 161, Issue 2, pp 143–151

Treatment strategies in patients with major depression not responding to first-line sertraline treatment

A randomised study of extended duration of treatment, dose increase or mianserin augmentation
  • Rasmus W. Licht
  • Susanne Qvitzau
Original Investigation

DOI: 10.1007/s00213-002-0999-0

Cite this article as:
Licht, R.W. & Qvitzau, S. Psychopharmacology (2002) 161: 143. doi:10.1007/s00213-002-0999-0


Rationale: A large proportion of patients with major depression do not respond sufficiently to any first-line treatment. Objectives: The aim of this study was to compare a strategy of sertraline dose increase with a strategy of adding mianserin in patients with major depression insufficiently responding to 6 weeks of open treatment with sertraline, controlling for the effect of an extended duration of treatment. Methods: One thousand six hundred and twenty-nine patients, 18–65 years of age, with major depression scoring at least 18 on the 17-item Hamilton depression scale (HDS) were treated openly with 50 mg/day sertraline, and patients who after 4 weeks had not responded (achieving at least a 50% reduction in score on the HDS) were treated with 100 mg/day sertraline for an additional 2-week period. The patients who had still not responded were then randomised to double-blind treatment for an additional 5 weeks with either 100 mg/day sertraline plus placebo, 200 mg/day sertraline plus placebo or 100 mg/day sertraline plus 30 mg/day mianserin. Results: After 6 weeks of open treatment, 60% had responded and 22% had dropped out, leaving 295 non-responding patients (18%) for randomisation. In the intention-to-treat-analysis, continuing the treatment with 100 mg/day sertraline resulted in response in 70% of the non-responders, similar to the response rate (67%) obtained in the patients who had mianserin added. However, increasing the sertraline dose to 200 mg/day resulted in a lower response rate at 56% (P<0.05). Similar results were seen in the completers. A substantial increase in the accumulated response rate from week 6 to week 8 was seen. There was no influence of baseline variables, including the presence of melancholic features on the overall post-randomisation response rate. Conclusion: After 6 weeks of insufficient antidepressant treatment with 50–100 mg/day sertraline, a continued treatment with 100 mg/day sertraline can be considered until at least week 8 before considering changing strategy, unless the condition deteriorates.

Drug combination Depressive disorder Mianserin Placebo Randomised controlled trial Sertraline Drug therapy 

Copyright information

© Springer-Verlag 2002

Authors and Affiliations

  • Rasmus W. Licht
    • 1
  • Susanne Qvitzau
    • 2
  1. 1.Mood Disorders Research Unit, Aarhus University Psychiatric Hospital, 8240 Risskov, Denmark
  2. 2.Pfizer A/S, Copenhagen, Denmark

Personalised recommendations